Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05558410 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Efficacy and Safety of Suzetrigine for Acute Pain After an Abdominoplasty
A Phase 3 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,118
- Enrollment target
NCT05558410: Completed Phase 3 study, sponsored by Vertex Pharmaceuticals Incorporated.
NCT05558410 is a Phase 3 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 1,118 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05558410, a Phase 3 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,118 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the efficacy and safety of Suzetrigine (SUZ) in treating acute pain after an abdominoplasty.
Primary Outcome
SPID was calculated as the sum of the product of time (in hours) elapsed since previous measurements and pain intensity difference. Pain intensity difference was calculated by subtracting the baseline pain intensity score from the pain intensity score at each postdose time point (using pain rating score range: 0 =no pain to 10 =worst possible pain). SPID48 was calculated from 0 to 48 hours and the score range was -480 (worst score) to 480 (best score).
Interventions
- DRUG Placebo (matched to SUZ)
- DRUG HB/APAP
- DRUG Placebo (matched to HB/APAP)
- DRUG Suzetrigine (SUZ)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,118 participants |
| Start Date | 2022-10-10 |
| Est. Completion | 2023-09-11 |
| Phase | Phase 3 |
What the finished NCT05558410 record still lists
NCT05558410 is an interventional study that assigns participants to a tested intervention. Its 1,118 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo (matched to SUZ) is the first listed.
NCT05558410 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05558410 about?
NCT05558410 is a clinical study titled "Evaluation of Efficacy and Safety of Suzetrigine for Acute Pain After an Abdominoplasty". The purpose of this study was to evaluate the efficacy and safety of Suzetrigine (SUZ) in treating acute pain after an abdominoplasty.
What is the current status of trial NCT05558410?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,118 participants. The study started on 2022-10-10. Estimated completion is 2023-09-11.
What interventions are being tested in trial NCT05558410?
The interventions under investigation include: Placebo (matched to SUZ) (DRUG), HB/APAP (DRUG), Placebo (matched to HB/APAP) (DRUG), Suzetrigine (SUZ) (DRUG).
Who is sponsoring clinical trial NCT05558410?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05558410's enrollment target sits among peer trials
1,118 249th of 2000 higher than 1,750 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02140255 · 1,120 participants · Phase 1
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
- NCT06618534 · 1,120 participants · Phase 2
Azithromycin for Meningococcal Carriage
- NCT07164131 · 1,120 participants · Phase 4
Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lactams
- NCT05691478 · 1,122 participants · Phase 2
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI